Gilead Sciences CFO Highlights YEZTUGO Launch, Arcellx Deal, and Long-Term Growth Potential

Gilead Sciences' CFO Andrew Dickinson highlighted the company's "long cycle" growth, citing recent launches, a broadening pipeline, and operating discipline. He emphasized the success of YEZTUGO and LIVDELZI, and the acquisition of Arcellx, a partner on anito-cel, a BCMA cell therapy for multiple myeloma. Dickinson framed the deal as driven by commercial opportunity and Gilead's view of anito-cel's profile, with estimated total multiple myeloma market for cell therapy exceeding $20 billion.